Nanologica is a Swedish life science company dedicated to providing benefits to patients, through the contribution of innovative products and processes based on nano-structured silica to the pharmaceutical industry. The company’s business strategy is to balance business areas of different risk profiles, including developing its own assets based on IPR generated with internal funding – advancing them to a stage where they can be spun out as their own entities. Today Nanologica is focusing on the two business areas Chromatography and Drug delivery, and develops delivery of biological molecules as an asset.


Figure 1: Nanologica’s proprietary NLAB SilicaTM is composed of micrometer-sized particles with a huge number of internal pores in the nanometer range.

In the business area Chromatography, Nanologica is developing and producing packing media for chromatography columns, consisting of highly porous silica particles in the size range between 1.5 µm and 5 µm. The packed columns are sold as consumables for analytical and preparative HPLC, with the pharmaceutical industry as the major end user. Nanologica’s product offers the industry improved performance in terms of speed and separation, allowing for improved development of pharmaceutical products.

Drug Delivery
In the Drug delivery business area, Nanologica is mainly focusing on using mesoporous silica, NLAB SilicaTM, for the improved delivery of APIs in oral dosage form. Up to 90% of all oral medicines in development today suffer from poor oral solubility, leading to poor bioavailability in the human body. In many cases the poor solubility can be improved with excipients that enhance the solubility of the APIs. Nanologica uses its deep knowledge and understanding of interactions between APIs and the materials in its NLAB SilicaTM portfolio in order to produce new pharmaceutical formulations with dramatic improvement in solubility. Nanologica conducts fee-for-service feasibility studies for pharmaceutical companies with poorly soluble APIs in their pipeline. Successful formulations are then developed further in partnership with the pharmaceutical company under a commercial agreement with appropriate IPR in place.

NLAB SilicaTM has shown potential for helping tackle one of the most pressing global issues of multi resistant bacteria which, if left unchecked, is destined to cause death at epidemic proportions. Reformulation and repurposing of antibiotics as well as combination therapies is conveniently well suited for NLAB SilicaTM, which offers protection and improved performance of often hard to formulate molecules.

Figure 2: Nanologica has successfully reformulated an HIV drug (Atazanavir, ATV) using NLAB SilicaTM, reducing its pH dependent solubility and dramatically improving its bioavailability in vivo.1

Delivery of biological molecules
NLAB SilicaTM is an ideal delivery vehicle for biologics, with the potential of ensuring controlled release of small biological compounds such as proteins and peptides. The major proof of this has been shown in delivery of peptide mimetics of growth factors for the regeneration of neuron stem cells in vivo in spinal cord injury models in mice. The results show that controlled and sustained release of growth factors from NLAB SilicaTM induces specific differentiation of the stem cells and increases their survival in vivo.2,3 These findings have the potential of revolutionizing the treatment of CNS injuries and neurodegenerative disorders. Nanologica is presently pursuing results from this research towards ALS therapy.

ALS    Amyotrophic lateral sclerosis
API    Active pharmaceutical ingredient
CNS    Central nervous system
HPLC    High-performance liquid chromatography
IPR    Intellectual property rights



1. ChemMedChem, 2012, 7: 43-48
2. Stem Cells Transl Med, 2:906-915. 2013
3. Nanomedicine 2014;9(16):2457-66

Forskargatan 20G, SE-151 36 Södertälje
+46 (0)8 4107 4949